By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nivalis Therapeutics (Formerly Known As N30 Pharma) 



Boulder  Colorado    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS








Company News
Cystic Fibrosis Biotech Nivalis Therapeutics Files for $60 Million IPO 5/14/2015 6:31:42 AM
N30 Pharma Announces Name Change To Nivalis Therapeutics 2/24/2015 8:14:37 AM
N30 Pharma Appoints Jon Congleton As President And CEO 12/22/2014 8:24:19 AM
N30 Pharma Secures $30 Million In Oversubscribed Crossover Financing 11/19/2014 11:40:46 AM
N30 Pharma Announces Presentations at the 2013 North American Cystic Fibrosis Conference 10/15/2013 6:13:57 AM
N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society 4/2/2013 9:25:21 AM
N30 Pharma Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis 3/13/2013 9:46:18 AM
N30 Pharma Names Sherif Gabriel, Ph.D. as Vice President of Research 10/8/2012 10:11:22 AM
N30 Pharma Announces Publication of S-Nitrosoglutathione Reductase Small Molecule Inhibitor Chemistry and Development 3/14/2011 8:21:49 AM
N30 Pharma to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting 3/2/2011 10:13:21 AM
12
//-->